Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&ABiotech ETFs Gain Momentum via AI Drug Discovery & Surging M&ABiotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A 

The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging. Furthermore, the industry is undergoing structural transformation amid a period of M&A activity. Key Takeaways The State Street SPDR S&P Biotech ETF (XBI) gained 17.9% in the first half of 2026, driven […]
The post Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A appeared first on ETF Trends.